Premenstrual Syndrome

The Treatment Effect of Peppermint Oil Capsule (Colpermin) for Premenstrual Syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016020926446N2

Enrollment

100

Registered

2016-03-23

Start date

2016-03-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenstrual Syndrom. Pain localized to other parts of lower abdomen

Interventions

Intervention 1: Peppermint Oil Capsule (Colpermin)187 mg BID for 10 days (from15 to beginning menstruation) for two cycle. Intervention 2: placebo (the same colpermin), BID for 10 days from15 to begin

Treatment - Drugs

Placebo

Peppermint Oil Capsule (Colpermin)187 mg BID for 10 days (from15 to beginning menstruation) for two cycle

placebo (the same colpermin), BID for 10 days from15 to beginning menstruation for two cycle

Eligibility

Sex/Gender

Female

Age

15 Years to 20 Years

Inclusion criteria

Inclusion criteria: 15-20 years old; mentally healthy; with no history of mental illness; ability to understand the questionnaire; regular menstrual cycles (21-35 days); no history of surgery and death of their relatives within the last 6 months; not taking antidepressants or anti-anxiety during last 3 months; no history of allergy to peppermint and its derivatives; a minimum score of 16 on the basis of Delany’s checklist 28 items is be determined.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mental symptoms. Timepoint: after 2 month end of consum of drugs. Method of measurement: Delany’s checklist.;Behavioral symptoms. Timepoint: after 2 month end of consum of drugs. Method of measurement: Delany’s checklist.;Physical symptoms. Timepoint: after 2 month end of consum of drugs. Method of measurement: Delany’s checklist.	—

Secondary

Measure	Time frame
Side effects of drugs such as complaints of heart bourn. Timepoint: end of treatment. Method of measurement: questionnaire.;Side effects of drugs such as complaints of allergic. Timepoint: end of treatment. Method of measurement: questionnaire.;Side effects of drugs such as complaints of hot flash. Timepoint: end of treatment. Method of measurement: questionnaire.;Side effects of drugs such as complaints of headaches. Timepoint: end of treatment. Method of measurement: questionnaire.;Side effects of mouth ulcer. Timepoint: end of treatment. Method of measurement: questionnaire.	—

Measure

Time frame

Side effects of drugs such as complaints of heart bourn. Timepoint: end of treatment. Method of measurement: questionnaire.;Side effects of drugs such as complaints of allergic. Timepoint: end of treatment. Method of measurement: questionnaire.;Side effects of drugs such as complaints of hot flash. Timepoint: end of treatment. Method of measurement: questionnaire.;Side effects of drugs such as complaints of headaches. Timepoint: end of treatment. Method of measurement: questionnaire.;Side effects of mouth ulcer. Timepoint: end of treatment. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMouloud Agajani Delavar

Babol University of Medical Sciences

moloodaghajani@yahoo.com+98 11 3236 0714

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026